CL2014001047A1 - Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas. - Google Patents

Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas.

Info

Publication number
CL2014001047A1
CL2014001047A1 CL2014001047A CL2014001047A CL2014001047A1 CL 2014001047 A1 CL2014001047 A1 CL 2014001047A1 CL 2014001047 A CL2014001047 A CL 2014001047A CL 2014001047 A CL2014001047 A CL 2014001047A CL 2014001047 A1 CL2014001047 A1 CL 2014001047A1
Authority
CL
Chile
Prior art keywords
pyrazine
respiratory
contain
composition
heterocyclic compounds
Prior art date
Application number
CL2014001047A
Other languages
English (en)
Spanish (es)
Inventor
Armin Heckel
Sara Frattini
Dieter Hamprecht
Joerg Kley
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2014001047A1 publication Critical patent/CL2014001047A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Hydrogenated Pyridines (AREA)
CL2014001047A 2011-11-02 2014-04-24 Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas. CL2014001047A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11187553 2011-11-02

Publications (1)

Publication Number Publication Date
CL2014001047A1 true CL2014001047A1 (es) 2014-11-07

Family

ID=47073464

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001047A CL2014001047A1 (es) 2011-11-02 2014-04-24 Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas.

Country Status (34)

Country Link
US (4) US8759349B2 (enExample)
EP (1) EP2773633B1 (enExample)
JP (1) JP6091513B2 (enExample)
KR (1) KR102006612B1 (enExample)
CN (2) CN104024244B (enExample)
AP (1) AP2014007670A0 (enExample)
AU (1) AU2012331274B2 (enExample)
BR (1) BR112014010583A2 (enExample)
CA (1) CA2854217C (enExample)
CL (1) CL2014001047A1 (enExample)
CO (1) CO6940429A2 (enExample)
CY (1) CY1120974T1 (enExample)
DK (1) DK2773633T3 (enExample)
EA (1) EA025158B9 (enExample)
EC (1) ECSP14001929A (enExample)
ES (1) ES2645744T3 (enExample)
GE (2) GEAP201813485A (enExample)
HR (1) HRP20171614T1 (enExample)
HU (1) HUE034929T2 (enExample)
IL (1) IL232035A (enExample)
LT (1) LT2773633T (enExample)
ME (1) ME02905B (enExample)
MX (1) MX348522B (enExample)
NO (1) NO2773633T3 (enExample)
PE (1) PE20141607A1 (enExample)
PH (1) PH12014500970B1 (enExample)
PL (1) PL2773633T3 (enExample)
PT (1) PT2773633T (enExample)
RS (1) RS56498B1 (enExample)
SG (1) SG11201401907TA (enExample)
SI (1) SI2773633T1 (enExample)
TN (1) TN2014000180A1 (enExample)
UA (1) UA115868C2 (enExample)
WO (1) WO2013064450A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
HRP20171614T1 (hr) * 2011-11-02 2017-12-01 Boehringer Ingelheim International Gmbh Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju
CA2915633A1 (en) * 2013-07-02 2015-01-08 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
EP3019492B1 (en) * 2013-07-08 2017-09-06 Boehringer Ingelheim International GmbH Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
JP6217866B2 (ja) * 2014-10-24 2017-10-25 小野薬品工業株式会社 Kcnq2〜5チャネル活性化剤
WO2016112120A1 (en) * 2015-01-07 2016-07-14 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
CN112107580A (zh) * 2020-09-29 2020-12-22 北京鑫开元医药科技有限公司 一种脾酪氨酸激酶抑制剂的制剂组合物及其制备方法
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
WO2024243025A1 (en) * 2023-05-19 2024-11-28 Ikena Oncology, Inc. Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6812003A (enExample) 1967-09-07 1969-03-11
US3953476A (en) 1971-12-27 1976-04-27 Merck & Co., Inc. 3-Amino-5-sulfonylbenzoic acids
CA2378181A1 (en) 1999-07-19 2001-01-25 Richard C. Boucher, Jr. Conjugates of sodium channel blockers and methods of using the same
AU2001229501A1 (en) 2000-01-24 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
KR20070059063A (ko) 2004-08-18 2007-06-11 마이클 알 존슨. 지방족 아미드 및 에스테르 피라지노일구아니딘 나트륨채널 차단제
GB0526244D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CA2658813A1 (en) * 2006-07-24 2008-01-31 International Stem Cell Corporation Synthetic cornea from retinal stem cells
KR20100005730A (ko) * 2007-05-07 2010-01-15 노파르티스 아게 유기 화합물
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
JP2011520831A (ja) * 2008-05-13 2011-07-21 ノバルティス アーゲー 3,5−ジアミノ−6−クロロ−ピラジン−2−カルボン酸誘導体および気道疾患処置用上皮性ナトリウムチャネルブロッカーとしてのその使用
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US9050339B2 (en) 2010-09-17 2015-06-09 Novartis Ag Pyrazine derivatives as ENaC blockers
PL2723176T3 (pl) 2011-06-27 2018-01-31 Parion Sciences Inc Chemicznie i metabolicznie stabilny dipeptyd o silnej aktywności blokera kanału sodowego
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
HRP20171614T1 (hr) * 2011-11-02 2017-12-01 Boehringer Ingelheim International Gmbh Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju
CN104024231A (zh) 2011-11-02 2014-09-03 勃林格殷格翰国际有限公司 制备酰基胍和酰基硫脲化合物的新方法

Also Published As

Publication number Publication date
ES2645744T3 (es) 2017-12-07
DK2773633T3 (da) 2017-11-13
JP6091513B2 (ja) 2017-03-08
US20150336933A1 (en) 2015-11-26
NZ622469A (en) 2016-08-26
PL2773633T3 (pl) 2018-01-31
HUE034929T2 (en) 2018-03-28
GEP20186880B (en) 2018-07-25
CY1120974T1 (el) 2019-12-11
TN2014000180A1 (en) 2015-09-30
US8759349B2 (en) 2014-06-24
PE20141607A1 (es) 2014-11-23
CN106279110B (zh) 2019-12-10
SI2773633T1 (sl) 2017-11-30
HK1196819A1 (zh) 2014-12-24
AU2012331274A1 (en) 2014-04-03
US9920035B2 (en) 2018-03-20
JP2014534222A (ja) 2014-12-18
KR20140085498A (ko) 2014-07-07
NO2773633T3 (enExample) 2017-12-30
US20140228374A1 (en) 2014-08-14
UA115868C2 (uk) 2018-01-10
HRP20171614T1 (hr) 2017-12-01
WO2013064450A1 (en) 2013-05-10
MX348522B (es) 2017-06-16
US20180194747A1 (en) 2018-07-12
AU2012331274B2 (en) 2017-06-08
BR112014010583A2 (pt) 2020-04-22
RS56498B1 (sr) 2018-01-31
CO6940429A2 (es) 2014-05-09
LT2773633T (lt) 2017-11-10
IL232035A (en) 2017-05-29
IL232035A0 (en) 2014-05-28
AP2014007670A0 (en) 2014-05-31
CA2854217A1 (en) 2013-05-10
PT2773633T (pt) 2017-11-14
CN104024244B (zh) 2016-09-14
ME02905B (me) 2018-10-20
PH12014500970B1 (en) 2017-10-06
EA025158B1 (ru) 2016-11-30
US20130109697A1 (en) 2013-05-02
PH12014500970A1 (en) 2014-06-09
CN106279110A (zh) 2017-01-04
SG11201401907TA (en) 2014-05-29
KR102006612B1 (ko) 2019-08-02
GEAP201813485A (en) 2018-04-10
MX2014005166A (es) 2014-05-28
CA2854217C (en) 2019-12-31
EA201400521A1 (ru) 2014-09-30
EP2773633B1 (en) 2017-08-02
EP2773633A1 (en) 2014-09-10
ECSP14001929A (es) 2015-11-30
EA025158B9 (ru) 2018-03-30
CN104024244A (zh) 2014-09-03

Similar Documents

Publication Publication Date Title
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2013001891A1 (es) Compuestos heterociclicos fusionados; composicion farmaceutica y uso en el tratamiento de la degeneracion macular asociada con la edad.
CL2015001702A1 (es) Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
EP3009432A4 (en) AMINOTRIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION WITH THESE DERIVATIVES
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2014003357A1 (es) Composición sinérgica para la protección de cultivos agrícolas y su uso
CL2015002860A1 (es) Antagonistas de la alfa-v-beta-6 integrina
CL2015000331A1 (es) Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal.
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
HRP20181855T1 (hr) Lipidi za formulacije namijenjene unosu terapijskog sredstva
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
CL2013002053A1 (es) Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
CL2013003472A1 (es) Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras.
CL2015000345A1 (es) Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2013001754A1 (es) Compuestos derivados de enonas triciclicas y tetraciclicas de pirazolilo y pirimidinilo; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias.
CL2015000408A1 (es) Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer.
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
CL2013001009A1 (es) Compuestos heterociclicos fusionados; composicion farmaceutica que los comprende, y uso en el tratamiento de un trastorno proliferativo tal como cancer.
CL2015001342A1 (es) Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.